Loading company…
Rznomics develops RNA-based gene therapies for cancer, neurological, and inherited eye diseases.
Founded in 2017 and based in Seongnam, South Korea, Rznomics develops RNA-based gene therapies using a trans-splicing ribozyme approach. Its drug research targets liver cancer, glioblastoma, Alzheimer's disease, and hereditary retinitis pigmentosa.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in